NFKBIA and diffuse large B-cell lymphoma: Bortezomib, a proteasome inhibitor blocking degradation of IκBα (an inactivator of NF-κB), showed clinical benefits in relapsed ABC-DLBCL patients when combined with DA-EPOCH-R (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, Rituximab) [59, 64].